Trial Profile
A Phase 1, Open Label, Randomized Study to Assess Pharmacokinetics, Biodistribution and Radiation Dosimetry of Lutetium (177Lu) Lilotomab Satetraxetan (Betalutin®) Radioimmunotherapy in Patients With Relapsed Non-Hodgkin Lymphoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lutetium-177 lilotomab satetraxetan (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Diagnostic use
- Acronyms LYMRIT-37-02
- Sponsors Nordic Nanovector
- 08 Jan 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 02 May 2018 Planned End Date changed from 1 Jul 2019 to 1 Sep 2020.
- 02 May 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.